专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5766599A Trova fowl pox virus recombinants comprising heterologous inserts 失效
标题翻译：特洛瓦家禽痘病毒重组体包含异源插入物
公开(公告)号：US5766599A
公开(公告)日：1998-06-16
申请号：US458101
申请日：1995-06-01
申请人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe Francis Audonnet , Russell Robert Gettig
发明人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe Francis Audonnet , Russell Robert Gettig
IPC分类号： A61K39/12 , A61K39/00 , A61K39/08 , A61K39/15 , A61K39/165 , A61K39/17 , A61K39/175 , A61K39/205 , A61K39/21 , A61K39/23 , A61K39/245 , A61K39/275 , A61K39/285 , A61K39/29 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , C07H21/04 , C07K1/00 , C07K14/015 , C07K14/02 , C07K14/03 , C07K14/035 , C07K14/045 , C07K14/05 , C07K14/06 , C07K14/065 , C07K14/07 , C07K14/11 , C07K14/12 , C07K14/125 , C07K14/145 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/175 , C07K14/18 , C07K14/33 , C12N7/00 , C12N7/01 , C12N7/04 , C12N7/08 , C12N15/00 , C12N15/09 , C12N15/86 , C12N15/863 , C12P21/06 , C12R1/93
CPC分类号： C12N15/86 , C07K14/005 , C07K14/33 , A61K2039/5254 , A61K39/00 , C07K2319/00 , C07K2319/02 , C07K2319/40 , C12N2710/16122 , C12N2710/16222 , C12N2710/16622 , C12N2710/16722 , C12N2710/24022 , C12N2710/24043 , C12N2710/24122 , C12N2710/24143 , C12N2730/10122 , C12N2740/13022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2750/14322 , C12N2760/12122 , C12N2760/16122 , C12N2760/18122 , C12N2760/18422 , C12N2760/18722 , C12N2760/20122 , C12N2770/24122 , C12N2770/24322 , Y10S530/826
摘要： What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
摘要翻译：描述的是具有增强的安全性的修饰载体，例如重组痘病毒，特别是重组痘苗病毒。修饰的重组病毒具有在其中灭活的非必需病毒编码的遗传功能，使得病毒具有减毒毒力。在一个实施方案中，通过删除编码毒力因子的开放阅读框来使遗传功能失活。在另一个实施方案中，通过插入失活编码毒力因子的开放阅读框来使遗传功能失活。还描述了含有在其中灭活的非必需病毒编码的遗传功能的修饰的重组病毒的疫苗，使得疫苗与已知重组病毒疫苗相比具有提高的安全性水平。

2. 发明授权

US5762938A Modified recombinant vaccinia virus and expression vectors thereof 失效
标题翻译：改良的重组痘苗病毒及其表达载体
公开(公告)号：US5762938A
公开(公告)日：1998-06-09
申请号：US709209
申请日：1996-08-21
申请人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe Francis Audonnet , Russell Robert Gettig
发明人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe Francis Audonnet , Russell Robert Gettig
IPC分类号： A61K39/12 , A61K39/00 , A61K39/08 , A61K39/15 , A61K39/165 , A61K39/17 , A61K39/175 , A61K39/205 , A61K39/21 , A61K39/23 , A61K39/245 , A61K39/275 , A61K39/285 , A61K39/29 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , C07H21/04 , C07K1/00 , C07K14/015 , C07K14/02 , C07K14/03 , C07K14/035 , C07K14/045 , C07K14/05 , C07K14/06 , C07K14/065 , C07K14/07 , C07K14/11 , C07K14/12 , C07K14/125 , C07K14/145 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/175 , C07K14/18 , C07K14/33 , C12N7/00 , C12N7/01 , C12N7/04 , C12N7/08 , C12N15/00 , C12N15/09 , C12N15/86 , C12N15/863 , C12P21/06 , C12R1/93
CPC分类号： C12N15/86 , C07K14/005 , C07K14/33 , A61K2039/5254 , A61K39/00 , C07K2319/00 , C07K2319/02 , C07K2319/40 , C12N2710/16122 , C12N2710/16222 , C12N2710/16622 , C12N2710/16722 , C12N2710/24022 , C12N2710/24043 , C12N2710/24122 , C12N2710/24143 , C12N2730/10122 , C12N2740/13022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2750/14322 , C12N2760/12122 , C12N2760/16122 , C12N2760/18122 , C12N2760/18422 , C12N2760/18722 , C12N2760/20122 , C12N2770/24122 , C12N2770/24322 , Y10S530/826
摘要： What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
摘要翻译：描述的是具有增强的安全性的修饰载体，例如重组痘病毒，特别是重组痘苗病毒。修饰的重组病毒具有在其中灭活的非必需病毒编码的遗传功能，使得病毒具有减毒毒力。在一个实施方案中，通过删除编码毒力因子的开放阅读框来使遗传功能失活。在另一个实施方案中，通过插入失活编码毒力因子的开放阅读框来使遗传功能失活。还描述了含有在其中灭活的非必需病毒编码的遗传功能的修饰的重组病毒的疫苗，使得疫苗与已知重组病毒疫苗相比具有提高的安全性水平。

3. 发明授权

US5759552A Marek's disease virus recombinant poxvirus vaccine 失效
标题翻译：马立克氏病病毒重组痘病毒疫苗
公开(公告)号：US5759552A
公开(公告)日：1998-06-02
申请号：US207792
申请日：1994-03-07
申请人： Enzo Paoletti , Jill Taylor , James Tartaglia , Louis Ross
发明人： Enzo Paoletti , Jill Taylor , James Tartaglia , Louis Ross
IPC分类号： A61K39/255 , A61K39/275 , A61K39/295 , C12N7/01 , C12N15/86
CPC分类号： A61K39/255 , A61K39/12 , C12N7/00 , A61K2039/5256 , C12N2710/16334 , C12N2710/24143 , C12N2710/24161
摘要： What is described is a recombinant poxvirus, such as vaccinia virus or fowlpox virus, containing foreign DNA from Marek's disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.
摘要翻译：描述的是重组痘病毒，如痘苗病毒或禽痘病毒，含有马立克氏病病毒的外来DNA。还描述了含有用于在接种疫苗的宿主动物中诱导免疫应答的重组痘病毒的疫苗。

4. 发明授权

US5756102A Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants 失效
标题翻译：疱疹病毒 - 犬瘟热病毒（CDV）重组体和使用重组体的组合物和方法
公开(公告)号：US5756102A
公开(公告)日：1998-05-26
申请号：US224657
申请日：1994-04-06
申请人： Enzo Paoletti , James Tartaglia , Jill Taylor
发明人： Enzo Paoletti , James Tartaglia , Jill Taylor
IPC分类号： C12N15/09 , A61K39/175 , A61K39/275 , A61K39/285 , A61P31/12 , C07K14/11 , C07K14/115 , C07K14/12 , C07K14/125 , C07K14/13 , C07K14/145 , C12N7/01 , C12N7/04 , C12N15/863 , C12P21/02
CPC分类号： C12N15/86 , C07K14/005 , C12N2710/24043 , C12N2710/24143 , C12N2760/16122 , C12N2760/18122 , C12N2760/18422 , C12N2760/18722 , C12N2760/20122
摘要： Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine distemper virus fusion protein and canine distemper virus hemagglutinin glycoprotein. The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus.
摘要翻译：含有编码犬瘟热病毒抗原的DNA的减毒重组病毒以及使用该病毒的方法和组合物被公开并要求保护。重组病毒可以是NYVAC或ALVAC重组病毒。 DNA可编码以下至少一种：犬瘟热病毒融合蛋白和犬瘟热病毒血凝素糖蛋白。重组病毒及其基因产物可用于引发针对犬瘟热病毒的保护。

5. 发明授权

US5494807A NYVAC vaccinia virus recombinants comprising heterologous inserts 失效
标题翻译： NYVAC痘苗病毒重组体包含异源插入片段
公开(公告)号：US5494807A
公开(公告)日：1996-02-27
申请号：US105483
申请日：1993-08-12
申请人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe F. Audonnet , Russell R. Gettig
发明人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe F. Audonnet , Russell R. Gettig
IPC分类号： A61K39/12 , A61K39/00 , A61K39/08 , A61K39/15 , A61K39/165 , A61K39/17 , A61K39/175 , A61K39/205 , A61K39/21 , A61K39/23 , A61K39/245 , A61K39/275 , A61K39/285 , A61K39/29 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , C07H21/04 , C07K1/00 , C07K14/015 , C07K14/02 , C07K14/03 , C07K14/035 , C07K14/045 , C07K14/05 , C07K14/06 , C07K14/065 , C07K14/07 , C07K14/11 , C07K14/12 , C07K14/125 , C07K14/145 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/175 , C07K14/18 , C07K14/33 , C12N7/00 , C12N7/01 , C12N7/04 , C12N7/08 , C12N15/00 , C12N15/09 , C12N15/86 , C12N15/863 , C12P21/06 , C12R1/93 , A61K39/295 , C12N15/63
CPC分类号： C12N15/86 , C07K14/005 , C07K14/33 , A61K2039/5254 , A61K39/00 , C07K2319/00 , C07K2319/02 , C07K2319/40 , C12N2710/16122 , C12N2710/16222 , C12N2710/16622 , C12N2710/16722 , C12N2710/24022 , C12N2710/24043 , C12N2710/24122 , C12N2710/24143 , C12N2730/10122 , C12N2740/13022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2750/14322 , C12N2760/12122 , C12N2760/16122 , C12N2760/18122 , C12N2760/18422 , C12N2760/18722 , C12N2760/20122 , C12N2770/24122 , C12N2770/24322 , Y10S530/826
摘要： What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
摘要翻译：描述的是具有增强的安全性的修饰载体，例如重组痘病毒，特别是重组痘苗病毒。修饰的重组病毒具有在其中灭活的非必需病毒编码的遗传功能，使得病毒具有减毒毒力。在一个实施方案中，通过删除编码毒力因子的开放阅读框来使遗传功能失活。在另一个实施方案中，通过插入失活编码毒力因子的开放阅读框来使遗传功能失活。还描述了含有在其中灭活的非必需病毒编码的遗传功能的修饰的重组病毒的疫苗，使得疫苗与已知重组病毒疫苗相比具有提高的安全性水平。

6. 发明授权

US07144578B2 Poxvirus-rabies recombinants and compositions and methods employing the recombinants 有权
标题翻译：痘病毒狂犬病重组体，以及采用重组体的组合物和方法
公开(公告)号：US07144578B2
公开(公告)日：2006-12-05
申请号：US09951061
申请日：2001-09-13
申请人： Enzo Paoletti , James Tartaglia , Jill Taylor , Russell Gettig
发明人： Enzo Paoletti , James Tartaglia , Jill Taylor , Russell Gettig
IPC分类号： A61K39/275 , A61K39/285 , C12N7/01 , C12N15/863 , C12N15/47
CPC分类号： C12N15/86 , A61K39/00 , A61K2039/525 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C07K14/33 , C07K2319/00 , C12N2710/16122 , C12N2710/16222 , C12N2710/16622 , C12N2710/16722 , C12N2710/24022 , C12N2710/24043 , C12N2710/24122 , C12N2710/24143 , C12N2730/10122 , C12N2740/13022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2750/14322 , C12N2760/12022 , C12N2760/16122 , C12N2760/18122 , C12N2760/18422 , C12N2760/18722 , C12N2760/20122 , C12N2770/24022 , C12N2770/24122
摘要： Recombinant viruses containing DNA coding for a rabies virus antigen, such as rabies virus G are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom are useful for eliciting an immunological against rabies virus, and, the gene products and antibodies elicited thereby are useful in assays.
摘要翻译：含有编码狂犬病病毒抗原的DNA的狂犬病病毒G的重组病毒被公开并要求保护。重组病毒可以是NYVAC或ALVAC重组病毒。重组病毒及其基因产物可用于引发针对狂犬病病毒的免疫学，并且由此引发的基因产物和抗体可用于测定。

7. 发明授权

US5756103A Alvac canarypox virus recombinants comprising heterlogous inserts 失效
标题翻译： Alvac金丝雀痘病毒重组体包含杂种插入物
公开(公告)号：US5756103A
公开(公告)日：1998-05-26
申请号：US457007
申请日：1995-06-01
申请人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe Francis Audonnet , Russell Robert Gettig
发明人： Enzo Paoletti , Marion E. Perkus , Jill Taylor , James Tartaglia , Elizabeth K. Norton , Michel Riviere , Charles de Taisne , Keith J. Limbach , Gerard P. Johnson , Steven E. Pincus , William I. Cox , Jean-Christophe Francis Audonnet , Russell Robert Gettig
IPC分类号： A61K39/12 , A61K39/00 , A61K39/08 , A61K39/15 , A61K39/165 , A61K39/17 , A61K39/175 , A61K39/205 , A61K39/21 , A61K39/23 , A61K39/245 , A61K39/275 , A61K39/285 , A61K39/29 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , C07H21/04 , C07K1/00 , C07K14/015 , C07K14/02 , C07K14/03 , C07K14/035 , C07K14/045 , C07K14/05 , C07K14/06 , C07K14/065 , C07K14/07 , C07K14/11 , C07K14/12 , C07K14/125 , C07K14/145 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/175 , C07K14/18 , C07K14/33 , C12N7/00 , C12N7/01 , C12N7/04 , C12N7/08 , C12N15/00 , C12N15/09 , C12N15/86 , C12N15/863 , C12P21/06 , C12R1/93
CPC分类号： C12N15/86 , C07K14/005 , C07K14/33 , A61K2039/5254 , A61K39/00 , C07K2319/00 , C07K2319/02 , C07K2319/40 , C12N2710/16122 , C12N2710/16222 , C12N2710/16622 , C12N2710/16722 , C12N2710/24022 , C12N2710/24043 , C12N2710/24122 , C12N2710/24143 , C12N2730/10122 , C12N2740/13022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2750/14322 , C12N2760/12122 , C12N2760/16122 , C12N2760/18122 , C12N2760/18422 , C12N2760/18722 , C12N2760/20122 , C12N2770/24122 , C12N2770/24322 , Y10S530/826
摘要： What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
摘要翻译：描述的是具有增强的安全性的修饰载体，例如重组痘病毒，特别是重组痘苗病毒。修饰的重组病毒具有在其中灭活的非必需病毒编码的遗传功能，使得病毒具有减毒毒力。在一个实施方案中，通过删除编码毒力因子的开放阅读框来使遗传功能失活。在另一个实施方案中，通过插入失活编码毒力因子的开放阅读框来使遗传功能失活。还描述了含有修饰的重组病毒的疫苗，其具有在其中灭活的非必需的病毒编码的遗传功能，使得疫苗与已知的重组病毒疫苗相比具有提高的安全性水平。

8. 发明授权

US06309647B1 Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants 有权
标题翻译：疱疹病毒 - 犬瘟热病毒（CDV）或麻疹病毒重组体以及使用重组体的组合物和方法
公开(公告)号：US06309647B1
公开(公告)日：2001-10-30
申请号：US09354138
申请日：1999-07-15
申请人： Enzo Paoletti , James Tartaglia , Jill Taylor , Russell Gettig
发明人： Enzo Paoletti , James Tartaglia , Jill Taylor , Russell Gettig
IPC分类号： A61K39275
CPC分类号： C12N15/86 , A61K39/00 , A61K2039/525 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C07K14/33 , C07K2319/00 , C12N2710/16122 , C12N2710/16222 , C12N2710/16622 , C12N2710/16722 , C12N2710/24022 , C12N2710/24043 , C12N2710/24122 , C12N2710/24143 , C12N2730/10122 , C12N2740/13022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2750/14322 , C12N2760/12022 , C12N2760/16122 , C12N2760/18122 , C12N2760/18422 , C12N2760/18722 , C12N2760/20122 , C12N2770/24022 , C12N2770/24122
摘要： Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen or measles M or N antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine distemper virus fusion protein, canine distemper virus hemagglutinin glycoprotein, canine distemper nucleocaspid protein, canine distemper matrix protein, measles virus nucleocaspid protein, and measles virus matrix protein. The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus and/or measles virus, and, the gene products and antibodies elicited thereby are useful in assays. Additionally, DNA from the recombinants is used for probes or for generating PCR primers.
摘要翻译：包含编码犬瘟热病毒抗原或麻疹M或N抗原的DNA的减毒重组病毒以及使用病毒的方法和组合物被公开和要求保护。重组病毒可以是NYVAC或ALVAC重组病毒。 DNA可以编码以下至少一种：犬瘟热病毒融合蛋白，犬瘟热病毒血凝素糖蛋白，犬瘟热核心蛋白蛋白，犬瘟热蛋白基因蛋白，麻疹病毒核壳蛋白和麻疹病毒基质蛋白。重组病毒及其基因产物可用于引发针对犬瘟热病毒和/或麻疹病毒的保护，由此引发的基因产物和抗体可用于测定。此外，来自重组体的DNA用于探针或产生PCR引物。

9. 发明授权

US5759553A Marek's disease virus recombinant poxvirus vaccine 失效
公开(公告)号：US5759553A
公开(公告)日：1998-06-02
申请号：US475063
申请日：1995-06-07
申请人： Enzo Paoletti , Jill Taylor , James Tartaglia , Louis Ross
发明人： Enzo Paoletti , Jill Taylor , James Tartaglia , Louis Ross
IPC分类号： A61K39/255 , A61K39/275 , A61K39/295 , C12N7/01 , C12N15/86
CPC分类号： A61K39/255 , A61K39/12 , C12N7/00 , A61K2039/5256 , C12N2710/16334 , C12N2710/24143 , C12N2710/24161
摘要： What is described is a recombinant poxvirus, such as vaccinia virus or fowlpox virus, containing foreign DNA from Marek's disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.

10. 发明授权

US6004777A Vectors having enhanced expression, and methods of making and uses thereof 失效
标题翻译：具有增强表达的载体及其制备和使用方法
公开(公告)号：US6004777A
公开(公告)日：1999-12-21
申请号：US815809
申请日：1997-03-12
申请人： James Tartaglia , Bertram L. Jacobs , Scott J. Goebel , William I. Cox , Russell Robert Gettig , Steven E. Pincus , Enzo Paoletti
发明人： James Tartaglia , Bertram L. Jacobs , Scott J. Goebel , William I. Cox , Russell Robert Gettig , Steven E. Pincus , Enzo Paoletti
IPC分类号： C12N15/09 , A61K35/76 , A61K48/00 , A61P37/04 , C12N15/67 , C12N15/85 , C12P21/02 , C12P21/00 , C12N15/11 , C12N15/63 , C12N15/66
CPC分类号： C12N15/67 , C12N15/85
摘要： Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially co-temporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid molecule encodes a translation factor. The contemporaneous expression can be from operably linking the first and second nucleic molecules to a single promoter, or from operably linking the first nucleic acid molecule to a first promoter and the second nucleic molecule to a second promoter wherein the first and second promoters function substantially contemporaneously. Thus, the first and second nucleic acid molecules can be at the same locus in the vector or at different loci. The second nucleic acid molecule can encode encode one translation factor or more than one translation factor. The translation factor can be a K3L open reading frame, an E3L open reading frame, a VAI RNA, an EBER RNA, a sigma 3 open reading frame, a TRBP open reading frame, or combinations thereof. The vector can be a poxvirus such as an attenuated poxvirus; for instance, a NYVAC vaccinia virus or an ALVAC canarypox virus.
摘要翻译：披露和要求保护的是具有增强的表达的载体和用于制备和使用它们的方法。表达的增强来自至少一种第一核酸分子和至少一种第二核酸分子的基本上同时表达。第二核酸分子编码翻译因子。同时表达可以是将第一和第二核酸分子可操作地连接到单个启动子，或者可操作地将第一核酸分子与第一启动子连接，而将第二核酸分子可操作地连接到第二启动子，其中第一和第二启动子基本同时起作用。因此，第一和第二核酸分子可以在载体中或在不同基因座处于相同位点。第二核酸分子可编码编码一个翻译因子或多于一个翻译因子。翻译因子可以是K3L开放阅读框，E3L开放阅读框，VAI RNA，EBER RNA，Sigma 3开放阅读框，TRBP开放阅读框或其组合。载体可以是痘病毒，如减毒痘病毒; 例如，NYVAC痘苗病毒或ALVAC金丝雀痘病毒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式